An anti-benzodiazepine monoclonal antibody has been used to demonstrate the existence of benzodiazepine-like molecules in the brain. Immunocytochemical experiments show that these molecules are neuronal and not glial and that they are ubiquitously distributed throughout the brain. Immunoblots indicate the presence of benzodiazepinelike epitopes in several brain peptides. Small benzodiazepinelike molecules were isolated from the brain soluble fraction by immunoaffinity chromatography. They block the binding of agonists, inverse agonists, and antagonists to the neuronal-type benzodiazepine receptor. The neurotransmitter ry-aminobutyric acid increases the affinity of the benzodiazepine receptor for the purified endogenous molecules. The results indicate that the immunoafIinity-purified molecules behave like the neuronal-type benzodiazepine receptor agonists. The purified molecules, however, do not inhibit the binding of tritiated Ro 5-4864 to the "peripheral-type" benzodiazepine receptor. The results demonstrate the existence of benzodiazepine-like molecules in the brain that bind to the benzodiazepine receptor.
These molecules are different from the endogenous benzodiazepine receptor ligands reported by others.
The mammalian brain has been shown to have receptors for benzodiazepines (BZDs) (1, 2) . One could ask, why has evolution provided the brain with receptors for these synthetic drugs (e.g., Valium, Librium, etc.)? Possibly the brain could produce endogenous BZD-like molecules that bind to the BZD receptors (BZDRs), modulating y-aminobutyric acid (GABA) neurotransmission. This notion is supported by the existence in the brain of endogenous opiate peptides, which were discovered after the discovery of the brain opiate receptors. A number of substances extracted from brain and other tissues bind to the BZDR-e.g., purines and purine nucleosides (3, 4) , nicotinamide (5), ,3-carbolines (6) , and a number of peptides and proteins of Mr 1500-70,000 (7) (8) (9) (10) (11) . However, there is no real evidence that these compounds play any physiological role as ligands for BZDR (12, 13) . Thus, purines, purine nucleosides, and nicotinamide displace diazepam binding to the receptor with an IC50 of -1 mM, whereas diazepam has a Kd in the nanomolar range. Although the ,B-carbolines have high affinity (Kd in the nanomolar range) and high specificity for BZDR, they are not natural brain constituents but are rather artifacts formed during tissue extraction (12, 13) . The best-characterized brain peptide that binds to BZDR is the diazepam-binding inhibitor (DBI), Mr 11,000. DBI has been purified and the amino acid sequence, including a 18 amino acid active fragment, is known (11, 14, 15) . DBI inhibits the binding of p-carbolines and BZDs to BZDR with Ki = 1-4 ,uM. The characterization of other proteins and peptides that displace [3H] diazepam binding to the brain BZDR is incomplete.
In this paper we describe the use of an anti-benzodiazepine monoclonal antibody (mAb) for the identification and preliminary characterization of BZD-like molecules that bind to the brain BZDR. Some of these results have been communicated in preliminary form (16) .
MATERIALS AND METHODS
The mAb to BZD, 21-7F9, was obtained after immunizing BALB/c mice with 3-hemisuccinyloxyclonazepam coupled to bovine serum albumin (BZD-BSA). The production of the hybridomas and the comparative study of the BZD binding properties of this and other antibodies will be reported elsewhere (38) . The hybridomas secreting mAbs to BZD were identified by assaying the conditioned culture media in three ways: (i) binding of 3H-labeled flunitrazepam (FNZ) tp the mAbs, (ii) antibody competition with tie [3H]FNZ binding to the brain membrane BZDR, and (iii) antibody binding to the 3-hemisuccinyloxyclonazepam conjugate with keyhole limpet hemocyanin (BZD-KLH) in a standard ELISA assay. The hybridomas were recloned by limiting dilution.
The mAb 21-7F9 (an IgM) was purified from ascites fluid by ammonium sulfate precipitation followed by gel exclusion chromatography on Sephacryl S300 (Pharmacia). The purified mAb 21-7F9, coupled to Bio-Rad Affi-Gel 10 (3.5 mg of antibody protein per ml of gel), was used for the isolation of BZD-like compounds. Brains of 20 Sprague-Dawley rats (30 days old; Taconic Farms, Germantown, NY) were homogenized in 60 ml of 5 mM Tris HCl, pH 8.1/0.3 mM phenylmethylsulfonyl fluoride/0.1 mM EGTA/20 ,g of trypsin inhibitor per ml/1 ,ug of pepstatin per ml. The homogenate was centrifuged at 100,000 x g for 90 min at 4°C and the supernatant was centrifuged at the same speed for 30 min. The final supernatant was adjusted to pH 7.4 by adding 4 ml of 1 M Tris HCl, pH 7.4. The extract was passed through a 5-ml immunoaffinity column (containing immobilized mAb 21-7F9) at a flow rate of6 ml/hr. The column was washed first with 50 ml of 50 mM TrisHCl, pH 7.4, containing the aforementioned protease inhibitors, followed by 25 ml of 50 mM Tris HCl, pH 7.4, containing 0.1 M NaCl and the protease inhibitors, and finally with 50 ml of H20. The retained material was eluted with 75 ml of 0.2 M acetic acid at a flow rate of 50 ml/hr. The eluate was dried uhder reduced pressure and dissolved in 5 ml of 50 mM Tris-HCI, pH 7.4. 
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The publication costs of this article were defrayed. in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. Fig. 1 Table 1 show that 21-7F9 has high affinity for many of the BZDR agonists but low affinity for BZDR antagonists (e.g., Ro 15-1788) and for inverse agonists (e.g., P-carbolines). Another noteworthy feature of 21-7F9 is its high binding affinity for both FNZ and Ro 5-4864. However, the affinity of the neuronal-type BZDR for Ro 5-4864 is very low, which shows that the binding sites of the mAb and the BZDR are similar but not identical. mAb 21-7F9 Binds to Neuronal Antigens with BZD-like Epitopes. Immunocytochemistry. Fig. 2 shows the distribution of the 21-7F9 binding to some selected brain areas and cell types. The antibody binds to molecules distributed throughout the brain that are present in neurons but not in glial cells. These molecules are in the perikarya and processes of many but not all neurons. Fig. 3 shows that the binding of mAb 21-7F9 to the brain molecules ( Fig. 3A) Hybridoma culture medium (50 ,l) was added to 450 ,ul of the radioligand in 50 mM Tris HCl, pH 7.4, and incubated for 1 hr at 4°C. The nonspecific binding was determined by using 1 ,uM unlabeled ligand. The specific binding is the difference between total and nonspecific binding. No radioligand binding to control mAbs was detected. The antibody-BZD complexes were precipitated with 7.5% (vol/vol) polyethylene glycol 8000, using 0.125% bovine gamma globulin as a carrier. The complexes were recovered by filtration through Whatman GF/B filters and the radioactivity was determined as described elsewhere (17) . Values are means and standard deviations of two experiments.
potency. Other effective blockers of 21-7F9 binding to brain tissue were Ro 11-6896, Ro 5-4864, diazepam, and Ro 11-6893 (not shown).
Immunoblotting. Fig. 4 shows that 21-7F9 binds to a number of peptides present in the homogenates of various brain regions. No qualitative differences between these regions were found. The molecular weights of the reactive peptides range between 20,000 and 300,000. The most abundant peptide with BZD-like epitopes is the Mr 100,000 one.
Some, peptides (including the Mr 100,000 species) are associated with a synaptosomal membrane fraction. (18, 20) . The binding of these antibodies was also done without and with (left and right strips) 1 ILM FNZ. The parental myeloma P3X63Ag8.6.5.3 culture medium was used as a negative control (extreme right strip). The immunoblotting procedure and the preparation of the SPM fraction were described elsewhere (20, 21) .
immobilized mAb does not bind any endogenous ligands, which might be present in the brain, for the peripheral-type BZDR (27) .
The blocking activity of the purified molecules for [3H]FNZ binding was retained by a second, identical, immunoaffinity chromatography column (not shown). Furthermore, in experiments in which only the buffer and not the brain extract was passed through the column, no activity was detected in the eluate. These experiments indicate that the activity blocking the binding of [3H]FNZ originated from the brain extract and was not an artifact introduced by the column. The possibility that mAb 21-7F9 was leaking from the column was ruled out not only by the previous experiments but also because the immunoaffinity-purified molecules did not bind [3H]FNZ. Table 3 shows that the inhibition of the binding of [3H]Ro 15-1788 to BZDR by the purified molecules is potentiated by GABA. In this regard, the behavior of the purified molecules is similar to that of the BZDs (receptor agonists)-e.g., diazepam (Table 3 )-but different from that of the fB-carbolines (inverse agonists) and antagonists (28 The reaction mixture was 410 Ag of rat brain membranes, the radioligand, and 100,u1 of the immunoaffinity column eluate in a total volume of 500 A.l of 50 mM Tris HCl, pH 7.4 at 40C. The membrane-bound radioligand was determined after filtration through a Whatman GF/B filter as described elsewhere (17) . Values are means and standard deviations of two experiments.
5-4864 to the neuronal-and glial-type receptors, respectively. Inosine can distinguish between the two receptor types. Nevertheless, the distinction is not as dramatic as the one made by the purified molecules (Tables 2 and 3 ). In a preliminary attempt to characterize the immunoaffinity-purified molecules, we found that their activity ([3H]FNZ binding inhibition) (i) is resistant to proteases (Pronase, leucine aminopeptidase, proteinase K, trypsin, and chymotrypsin); (ii) is resistant to heating for 5 min at 100TC; and (iii) has the mobility of a Mr 1000 molecule (tentative), as determined by gel exclusion chromatography.
DISCUSSION
We have shown in this study that (i) the brain has a family of neuronal molecules with BZD-like epitopes that can be recognized by the anti-BZD mAb 21-7F9 and (ii) the brain molecules purified by immunoaffinity chromatography on the immobilized mAb 21-7F9 block [3H]FNZ binding to the brain BZDR. The purified molecules specifically bind to the BZDbinding site of the neuronal-type BZDR and behave as agonists.
The immunocytochemical experiments indicate that the endogenous molecules are localized in many neurons but not in glial cells. Distribution throughout the brain is consistent with their possible role as modulators of GABA neurotransmission: it has been estimated that up to 40%o of the brain synapses are mediated by GABA (29) , and GABA and the GABA-synthesizing enzyme glutamate decarboxylase are ubiquitously distributed in the brain. Some neurons that show 21-7F9 immunoreactivity (Fig. 2 B , C, and D) do not contain glutamate decarboxylase-e.g., the pyramidal neurons of the cerebral cortex (30) and hippocampus (31) and the granule cells of the dentate gyrus (32) . However, other GABA-ergic neurons such as the Purkinje, basket, stellate, and Golgi cells in the cerebellum showed reactivity with mAb 21-7F9 ( Fig.  2A) . It is worth noting that almost identical distributions of immunoreactivity in the cerebellum were observed with anti-BZD mAb and an antiserum to GABA (33) .
Our present strategy is to purify the smallest BZD-like molecules, which should be the easiest to characterize chemically. They are found in the soluble fraction and therefore they are the ones purified by immunoaffinity chromatography. In contrast, the larger peptides with BZDlike epitopes are associated to the membrane fraction. The activity of the immunoaffinity-purified BZD-like molecules is protease-resistant and thermostable, but these properties do not rule out a peptide, for there are examples of small peptides with similar properties (e.g., thyrotropin-releasing hormone, TRH). The relationship between the purified molecules and the peptides that are recognized by the antibody 21-7F9 in the immunoblots is unknown. We do not know yet whether the former are derived from the latter and whether the immunoblotted peptides are related to each other such that the larger are precursors of the smaller. Enkephalins, endorphins, and dynorphins have Mr 30,000 precursor peptides (34) , and the epidermal growth factor precursor is a protein of 130,000 Mr (35) . It has recently been reported that antibodies to neuropeptide-related antigens bind to a neuronal membrane glycoprotein of 100,000 Mr, and it has been suggested that this glycoprotein could be a precursor of smaller neuropeptides (36) . This resembles our finding that mAb 21-7F9 recognizes a Mr 100,000 synaptosomal mem- (37) .
The immunological approach has a number of advantages, which include not only the characterization of the peptides size but also the study of the cellular and subcellular localization of the BZD-like molecules and their purification by immunoafflinity chromatography. This approach has allowed us to identify a family of endogenous BZD-like molecules different from all the other putative endogenous BZDs reported in the literature. Thus, the pharmacological properties of our immunoaffinity-purified molecules differ from those of the DBI peptide (11): (i) whereas DBI binds to the ,3-carboline site of the BZDR, the immunoaffinity purified BZD-like molecules bind to the BZD (agonist) binding site, and (ii) the activity of our preparation, unlike that of DBI, is Pronase resistant (14) . Thus, unlike DBI and p-carbolines, the molecules recognized by mAb 21-7F9 probably potentiate the inhibitory effect of GABA on the GABA synapses.
The results presented in Tables 2 and 3 also show that the purified molecules are different from nicotinamide, hypoxanthine, and purine nucleosides, which have been suggested to be endogenous BZDs (3) (4) (5) . Moreover, whereas the combined concentrations of these substances in our brain extract would not exceed 50 ,uM (3) (4) (5) , their binding affinities for mAb 21-7F9 are very low (Kd = 2-10 mM). Even assuming 100% recovery after immunoaffinity chromatography, their combined concentration in the [3H]FNZ binding assay would be less than 100 ,iM. At this concentration, we observed no effect of the aforementioned substances on the [3H]FNZ binding to the membranes (not shown). In contrast, our preparations of endogenous BZD-like molecules still retained >50% of the initial inhibitory activity after a 1:10 dilution.
The results indicate that we have identified a class of endogenous BZD-like neuronal molecules that bind to the neuronal BZDR and that this binding is potentiated by GABA. We cannot yet rule out the possibility that the active substance is a BZD that might be present in the controlled rat diet and accumulates in the brain. However, if these substances are synthesized in the brain, then we predict that hypofunction of the brain endogenous BZD system (i.e., decreased synthesis or release, increased degradation, or decreased affinity for the receptor) might lead to pathological forms of anxiety and to the forms of epilepsy that respond to BZD treatment.
